Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Alterity Therapeutics Ltd ADR (ATHE)

Alterity Therapeutics Ltd ADR (ATHE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report PR Newswire - Tue Jan 31, 2023

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy PR Newswire - Mon Jan 9, 2023

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) PR Newswire - Fri Jan 6, 2023

/PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum PR Newswire - Tue Jan 3, 2023

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office PR Newswire - Thu Dec 29, 2022

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting PR Newswire - Mon Nov 7, 2022

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 1.2100 (+0.83%)
Appendix 4C - Q1 FY23 Quarterly Cash Flow Report PR Newswire - Fri Oct 28, 2022

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting PR Newswire - Wed Oct 26, 2022

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy PR Newswire - Thu Oct 13, 2022

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 1.2100 (+0.83%)
Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders PR Newswire - Mon Sep 26, 2022

/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...

ATHE : 1.2100 (+0.83%)

Barchart Exclusives

Natural Gas- Will European Prices Impact U.S. Prices During the Peak Season? Barchart - 12 minutes ago
Natural gas prices are moving into the peak demand season at low levels. After reaching record highs in Europe in 2022 and probing around the $10 level in the U.S., prices have declined to levels where the downside could be limited. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot